2022

RESCON - - SUMMIT

Inhalation & Respiratory drug delivery
Wearable injectors & Connected devices

6 – 7 OCT 2022

75 Rocketeller Plaza, 31st Floor – New York, Manhattan, USA

Sponsored by

Harro Höfliger

MUNIT
WE ARE MICRONIZATION

Catalent®

intertek
Total Quality. Assured.

gerresheimer

proveris
SCIENTIFIC

SensAIR™

gerresheimer

Customisable on-body delivery device

Re-usable disposable device parts
Adjustable pre-programmed dosing
Basal and / or bolus profile


PGIM FUNDS:
POWERED BY
PGIM INVESTMENTS
新华通讯社
XINHUA
XINHUA
NEWS AGENCY
NOVOTEL
THE
LION
KING
GET TICKETS
AT THE
MINSKOFF
THEATRE
LATER
TATERS
LG
OLD NAVY
ICE & VICE
CRAFT ICE CREAM
5%
TO CHARITY
STRAND

RESCON SUMMIT highlights innovations in the respiratory sector and connected devices. At the event we will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses at on-body device design and development for large volume delivery while engaging in the latest digital applications for wearable devices.

Key Practical Points

- Market introduction of the new Respiratory devices in Europe and USA
- Best practices for designing and evaluating smart medical devices
- Human factors engineering to improve devices' use-safety and usability
- Developing Biologics for Respiratory Delivery
- Case studies on Soft Mist Inhalers (SMI)
- Capsules for DPI formulations
- Powder dosing and DPI manufacturing
- Regulatory landscape for connected drug delivery device
- Biocompatibility evaluation of breathing gas pathways
- Biocompatibility requirements for inhalation drug-device combination products
- Advantages and challenges of inhaled drug delivery
- Respiratory Therapy for Managing Chronic Cough
- Innovative solution of an eFlow technology nebulizer
- Innovations in inhalation drug delivery
- Performance of Orbital device and formulation combination
- Advanced Drug Delivery Systems for Patient Centric Medication
- Environmental sustainability challenge to the inhalation devices industry
- Liquid Crystal Polymers
- Auto-injector for Asthma exacerbations

Speakers

FELIX WEILAND

Director Device Technology
at Boehringer Ingelheim microParts

BRYCE BEVERLIN II

CEO
at Quench Medical

JUSTIN KALAFAT

Head of International Scientific Business Development
at ACG

BERNHARD MÜLLINGER

General Manager, COO
at Resyca

MARCO FRANZA

Sales & Director Inhalation
at Berry Global

EMILY RESSEGUIE

Scientific Specialist - Inhalation Toxicologist
at Labcorp

VALERIE THOMAS

Sr. Principal Scientist- Nonclinical Drug Safety
at Merck & Co.

DON SMITH

Inventor and Founder
at 1nhaler

NITESH KUNDA

Assistant Professor
at Department of
Pharmaceutical Sciences,
St. John's University

DAVID EDWARDS

Founder
at FEND

MICHAEL CASTAGNA

Chief Executive
Officer
at MannKind
Corporation

MARK PARRY

Technical Director
at Intertek Melbourn

JAN DE BACKER

CEO
at Fluidda

IRENE ROSSI

Head of New Modalities
Pharmaceutical
Development
at Nanopharm, an Aptar
Company

VIVEK GUPTA

Scientific Founder
at PulmoSIM
Therapeutics

MARIAN ASCH

Sales Manager Inhalation
Technologies
at Harro Höfliger

CARLA VOZONE

VP Inhalation Strategy,
Innovation and
Partnerships at Catalent
Pharma Solutions

PHILIP WILSON

Marketing Director
at Celanese

YVONNE LIMPENS

Managing Human
Factors Specialist
at Emergo by UL

AMELIA YANG

Senior Consultant
at Beyond Conception

DONALD ZINN

VP US Business
at Crossject SA

CHARLES DUCKER

Principal Chemist/
Group Leader,
Extractables
and Leachables
at Eurofins

HOLGER KRENZ

Vice President Global
Business Development
High Value Products
at Gerresheimer

CAROLA FUCHS

Director e-Health
Solutions
at PARI Medical
Holding GmbH

INGO WASCHULEWSKI

International Business
Development & Sales
Manager
at Gerresheimer

MAHENDRA SHAH

Senior Fellow
at Vivo Capital

DEEPIKA LAKHANI

Vice President of
Regulatory & Quality
at PAVmed Inc



SCIENTIFIC AGENDA

Day I October 06, 2022

Morning sessions Chairperson: *Felix Weiland, Director Device Technology at Boehringer Ingelheim*

8:00 - 8:30

Registration and Welcome Coffee

8:30 - 9:10

Market introduction of the new Respimat Reusable technology in Europe

*By **Felix Weiland**, Director Device Technology at **Boehringer Ingelheim microParts***

9:10 - 9:50

"How was I supposed to know?" Common use errors and pitfalls when developing home-healthcare smart medical devices.

*By **Yvonne Limpens**, Managing Human Factors Specialist at **Emergo by UL***

9:50 - 10:10

Speed Networking

10:10 - 10:40

Morning Coffee-Break

10:40 - 11:20

Developing Biologics for Respiratory Delivery – Real World Lessons And Examples

*By **Mark Parry**, Technical Director at **Intertek Melbourn***

11:20 - 11:50

Soft Mist Inhalers (SMI) – Unmet needs in the development of inhaled products

*By **Bernhard Müllinger**, General Manager, COO at **Resyca***

11:50 - 12:30

Powder dosing and DPI manufacturing

*By **Marian Asch**, Sales Manager Inhalation Technologies at **Harro Höfliger***

12:30 - 13:00

Regulatory landscape for connected drug delivery device

*By **Amelia Yang**, Senior Consultant at **Beyond Conception***

13:00 - 14:00

Lunch Break

Afternoon sessions Chairperson: *Carla Vozone, VP Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions*

14:00 - 14:30

ISO18562_2017: "Biocompatibility evaluation of breathing gas pathways in healthcare applications"

*By **Charles Ducker**, Principal Chemist/ Group Leader, Extractables and Leachables at **Eurofins***

14:30 - 15:00

Satisfying Biocompatibility requirements for inhalation drug-device combination products

*By **Valerie Thomas**, Sr. Principal Scientist-Nonclinical Drug Safety at **Merck & Co.***

15:00 - 15:30

Orally Inhaled & Nasal Drug Delivery – New Realities, New Opportunities

*By **Carla Vozone**, VP Inhalation Strategy, Innovation and Partnerships at **Catalent Pharma Solutions***

15:30 - 16:00

Novel dry powder inhalation platform technology

*By **Bryce Beverlin II**, CEO at **Quench Medical***

16:00 - 16:30

Afternoon Coffee-Break

16:30 - 17:30

Panel Discussion

- Artificial Intelligence/Machine Learning in Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives
- Collaboration and Simplification to Accelerate Device Development and Drug Delivery.
- Inhaled Medicines: Past, Present, and Future
- Regulatory Strategy for Combination Devices: Working with the FDA for Program Success

Panelists:

- *Felix Weiland, Director Device Technology at Boehringer Ingelheim microParts*
- *Deepika Lakhani*, Vice President of Regulatory & Qualityat PAVmed Inc
- *Mahendra Shah, Senior Fellow at Vivo Capital*
- *Michael Castagna, Chief Executive Officer at MannKind Corporation*
- *Valerie Thomas, Sr. Principal Scientist- Nonclinical Drug Safety at Merck & Co.*
- ***Moderated by: Carla Vozone, VP Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions***

17:30

Chairperson Closing Remarks
and end of the 1st day sessions

20:30 - 22:30

Gala Dinner

Location: Beast & Butterflies | 226 W 52nd St, New York, NY 10019 (5 minute walk from 75 Rockefeller Plaza).

Day 2 October 07. 2022

Morning sessions Chairperson: *Don Smith, Inventor and Founder at 1nhaler*

8:00 - 8:30

Registration & Coffee

8:30 - 9:00

Invention, innovation and imposition. The unconventional story of the 1nhaler.

*By **Don Smith**, Inventor and Founder at **1nhaler***

9:00 - 9:30

Respiratory Therapy for Managing Chronic Cough

*By **David Edwards**, Founder at **FEND***

9:30 - 10:00

The use of the needle-free auto-injector ZENEO Terbutaline for Asthma exacerbations

*By **Donald Zinn**, VP US Business at **Crossject SA***

10:00 - 10:30

Morning Coffee-Break

10:30 - 11:00

Innovations in inhalation drug delivery

*By **Nitesh Kunda**, Assistant Professor at **St. John's University***

11:00 - 11:30

Adherence to nebulizer therapies and how connected nebulizers and objective adherence data can be beneficial for use in clinical trials and in commercial use

*By **Carola Fuchs**, Director e-Health Solutions at **PARI Medical Holding GmbH***

11:30 - 12:00

Assessment of the performance of a high payload device in combination with different model formulations

*By **Irene Rossi** Head of New Modalities Pharmaceutical Development at **Nanopharm, an Aptar Company***

12:00 - 13:00

Panel Discussion

- Injection Devices: Trends Influencing Development & Delivery
- Advances in Drug Delivery and Areas for Improvement
- Innovation on Large Volume Wearables: Market & Trends
- Managing the next pandemic: the role of nasal vaccine administration

Panelists:

- *Carola Fuchs, Director e-Health Solutions at PARI Medical Holding GmbH*
- *Nitesh Kunda, Assistant Professor at St. John's University*
- *Donald Zinn, VP US Business at Crossject SA*
- *Jan De Backer, CEO at Fluidda*
- *Holger Krenz Vice President Global Business Development High Value Products at Gerresheimer*
- ***Moderated by: Irene Rossi Head of New Modalities Pharmaceutical Development at Nanopharm, an Aptar Company***

13:00 - 14:00

Lunch Break

Afternoon sessions Chairperson: *Irene Rossi Head of New Modalities Pharmaceutical Development at Nanopharm, an Aptar Company*

14:00 - 14:30

A novel system solution approach: Cartridge-based Advanced Drug Delivery Systems for Patient Centric Medication

*By **Holger Krenz** Vice President Global Business Development High Value Products at **Gerresheimer** and **Ingo Waschulewski** International Business Development & Sales Manager at **Gerresheimer***

14:30 - 15:00

Modulating Physicochemical Parameters of Drug-Conjugated Microparticles for Enhanced Lung Deposition & Efficacy of Inhaled Therapeutics

*By **Vivek Gupta**, Associate Professor, and Scientific Founder at **St. John's University; PulmoSIM Therapeutics***

15:00 - 15:30

The environmental sustainability challenge to the inhalation devices industry

*By **Marco Franza**, Sales & Director Inhalation at **Berry Global***

15:30 - 16:00

In-vitro/In-silico bio-equivalence trials as alternatives to clinical endpoint studies

*By **Jan De Backer** CEO at **Fluidda***

16:00 - 16:30

Afternoon Coffee-Break

16:30 - 17:00

Liquid Crystal Polymers for the miniaturization of wearable and implantable biosensors

*By **Philip Wilson**, Marketing Director at **Celanese***

17:00 - 17:30

Inhalation 101

*By **Emily Resseguie**, SInhalation Toxicologist at **Labcorp***

17:30 - 18:00

What's so special about capsules for DPI formulations?

*By **Justin Kalafat**, Head of International Scientific Business Development at **ACG***

18:00

Chair's Closing Remarks & End of the RESCON Summit

Biographies

Amelia Yang, Senior Consultant at Beyond Conception

Amelia Yang, MSc, is a regulatory affairs consultant at Beyond Conception. Started from submissions for small molecules of various dosage forms, she went on to work on drug-device combination products, with and without connectivity. She has experiences in regulatory affairs as the sponsor of the drug constituent as well as the device constituent of a combination product.

Bernhard Müllinger, General Manager, COO at Resyca

Bernhard is the General Manager and Chief Operations Officer of Resyca and is based in Munich. Bernhard has experience with smart nebuliser devices and has worked in this industry for most of his career. He has extensive knowledge in medical device development and clinical development of combination products. Prior to joining Resyca, Bernhard worked at Vectura, Activaero, Inamed-CRO, Asklepios Clinic and Helmholtz-Zentrum.

Bryce Beverlin II, CEO at Quench Medical

Bryce Beverlin II founded Quench Medical to solve crucial problems in respiratory drug delivery for treating lung diseases. He is driven by a passion to help patients with lung diseases by developing the next-generation of highly performing treatments. Bryce is a physicist entrepreneur with 15 years of cross-functional R&D experience with a physics Ph.D. and medical commercialization training as a postdoctoral Senior Innovation Fellow from the University of Minnesota.

Carla Vozone, VP Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions

Carla Vozone is Vice President of Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions. Carla leads strategic growth initiatives for Catalent's Inhalation business segment and oversees Product Development for Nasals and Inhaled Powders. She holds a PharmD and MSc in Pharmaceutical Technology from the Pharmacy School, University of Lisbon, a Master in Business Administration (MBA) with a specialization in Pharmaceutical Management from Rutgers Business School, New Jersey and a Certification in Business Development and Licensing from the University of Manchester. Carla is Immediate Past Chair of IPAC-RS, the leading industry consortium on regulatory science of orally inhaled and nasal drugs (OINDPs).

Carola Fuchs, Director e-Health Solutions at PARI Medical Holding GmbH

Carola is leading the e-Health department at PARI and responsible for development, life cycle management, business development and management of all e-Health activities of the PARI Group. She has joined PARI after working for Sanofi and a biotech start-up in 2006 and started her first work on connected devices back then as a project leader at PARI Pharma.

Charles Ducker, Principal Chemist/Group Leader, Extractables and Leachables at Eurofins

Dr. Charles Ducker is a Group Leader for Eurofins Extractables and Leachables group where he performs extractables and leachables testing using LC/MS-TOF, LC/MS/MS, GC/MS, ICP/MS and ICP-OES technology. Specializing in LC/MS analysis, Dr. Ducker has 20 years of experience in the biotech industry and has earned a Ph.D. in Biochemistry/Molecular Biology from The Pennsylvania State University, as well as a B.S. in Biology from Millersville University.

David Edwards, Founder at FEND

David A. Edwards PhD is a pioneer of inhaled aerosols, long-standing faculty member at Harvard University (2001-2019), and founder of multiple respiratory healthcare startups including his most recent company, Sensory Cloud, pioneering upper airway hydration for respiratory health (hellofend.com).
A member of the national academes of engineering in the US and France, member of the National Academy of Inventors, and Chevalier of Arts & Sciences by the French Ministry of Culture, David is a prolific inventor, writer and speaker internationally.

Deepika Lakhani, Vice President of Regulatory & Qualityat PAVmed Inc

Deepika A. Lakhani serves as the Vice President of Regulatory & Quality, at PAVmed Inc. She was appointed to the position in 2022. Prior to her current role, Deepika was at AstraZeneca Pharmaceuticals in Global Regulatory Affairs and has spent nearly 11 years at the FDA where she started as a reviewer in Center for Drugs Evaluation and Research (CDER) and subsequently served in multiple positions in CDER and Center for Devices and Radiological Health (CDRH) involved with the review of medical devices, drugs, biologics, and combination products. Deepika considers regulatory affairs to be a creative process that enables innovation. She has multiple peer-reviewed publications, received many awards for excellence and leadership while at the FDA and still serves on the FDA Alumni Association. She holds a Ph.D. in Pharmaceutics from the Aerosol Research Group, Virginia Commonwealth University.

Donald Zinn, VP US Business at Crossject SA

Donald Zinn has 25 years of experience in building biotech, pharmaceutical and medical device companies from benchtop to the marketplace, generating and cultivating business relationships, developing and implementing business strategies, fundraising, and executing deals. Don was the US Head of Innovation for Rentschler Biopharma, CEO of Aursos and AzoRX, co-Founder of Artesian Therapeutics and Genetic Immunity.

Don Smith, Inventor and Founder at 1nhaler

Don Smith is the inventor of the 1nhaler, a revolutionary, single dose, dry powder inhaler, designed to deliver a global impact through a simpler, more convenient, user-focused approach to inhaler design.
The business is one of Scottish Enterprise's High Growth Ventures Portfolio companies, and Don runs the business alongside partner and Commercial Director Lisa McMyn, with support from an experienced team of respiratory industry experts.

Emily Resseguie, Inhalation Toxicologist at Labcorp

Emily joined Labcorp (formerly Envigo) as a Study Director and was responsible for the overall design, conduct, interpretation, and reporting of general toxicity studies, with an emphasis on inhalation studies, in both rodent and non-rodent species. After about 4 years she became an Inhalation Toxicologist within the company and now provides scientific leadership and strategy primarily for inhalation toxicology. She is responsible for training and mentoring of staff, and oversite of data acquisition, analysis, and reporting for the specialty. She published first author and co-author peer-reviewed articles, and was a member of the American Thoracic Society and Society of Toxicology while pursuing her doctorate.

Felix Weiland, Director Device Technology at Boehringer Ingelheim microParts

Dr. Felix Weiland is a pharmacist by training with a PhD in pharmacology. In 2006, he joined Boehringer Ingelheim as a trainee, focusing on launch and transfer activities of inhalative products. In 2010 he joined the Gerresheimer Group at Bünde as a QC head and later quality director. Buende is a large-scale manufacturing site of sterile primary packaging components, i.e.RTF®- syringes and insulin cartridges. In 2015, he returned to Boehringer Ingelheim microParts in Dortmund to implement structures for systematic life cycle management of the Respimat® Platform Technology, including development and launch of the Respimat Reusable Soft Mist Inhaler.

Holger Krenz, Vice President Global Business Development High Value Products at Gerresheimer

Holger Krenz, Vice President Global Business Development High Value Products, at Gerresheimer is responsible with his global team to drive the Gerresheimer growth strategy with a focus on RTU products and system solutions selling. He is responsible to enlarge Gerresheimer´s global footprint to strengthen the market position as leading company for primary packaging and drug delivery devices. Holger is working for more than 20 years in the medical device industry in various positions including R&D project management, Marketing & Sales as well as Business Development at different companies e.g. Boehringer Ingelheim and WestRock / Silgan Dispensing. In 2022 he joined Gerresheimer.

Ingo Waschulewski, International Business Development & Sales Manager at Gerresheimer

Ingo received his PhD in human biology from the University of Marburg, Germany and a Master of Science (MS) in nutritional sciences form the University of Arizona, USA. He has over 20 years of experience in the medical device, pharmaceutical & in-vitro diagnostics industries (i.e. working for international companies such as Alere now Abbott & Siemens Healthineers) – in areas such as global business development, sales, key account management & marketing.

Irene Rossi, Head of New Modalities Pharmaceutical Development at Nanopharm, an Aptar Company

Irene Rossi is Head of New Modalities Pharmaceutical Development at Nanopharm, an Aptar Company where she leads a group focused on the development of new technologies for OINDP products comprising biologics and chemical entities.Having achieved a Master in Pharmaceutical Chemistry and Technology, Irene spent 6 years at the University of Parma working on formulation development of nasal and inhalation products, particularly focusing on particle engineering.

Justin Kalafat, Head of International Scientific Business Development at ACG

Based in the US and responsible for leading a team in the Americas and Europe, Justin Kalafat is ACG Capsules' Head of International Scientific Business Development. His team collaborates with the pharmaceutical and dietary supplement industries targeting science driven customers for empty hard shell capsule opportunities and partnerships.

Jan De Backer, CEO at Fluidda

Jan De Backer graduated from Delft University of Technology, The Netherlands as aerospace engineer. He attained an MSc degree in aerodynamics and specialized in applied biomedical computational fluid dynamics leading to a PhD from the University of Antwerp, Belgium.
He is an alumnus of the MBA programs at London Business School, London and Columbia Business School, New York. Dr. De Backer has received several awards for his innovative research in the field of airway modeling in respiratory and sleep medicine. His work has been published in international journals.
Dr. De Backer founded FLUIDDA in 2005 and he has held the position of Chief Executive Officer since 2007.

Marco Franza, Sales & Director Inhalation at Berry Global

Marco Franza always worked in the commercial area covering different roles in Sales, Business Development and Marketing.
As inhalation devices have constantly been identified as a key growth factor for the company, Marco always had a particular focus on them, driven also by passionate personal interest.

Mahendra Shah, Senior Fellow at Vivo Capital

Mahendra G. Shah, Ph.D. is a highly successful pharmaceutical entrepreneur and executive who has been at Vivo Capital since March 2010. He is also the founder and executive chairman of Semnur Pharmaceuticals. Dr. Shah currently serves as chairman of the board of Essentialis Therapeutics, board member of Biotie Therapies (NASDAQ: BITI), and a member of the board of trustees of St. John's University. He is also a board member and charter member of EPPIC and a charter member of TIE. From September 2005 to December 2009, he was the founder, chairman and CEO of NextWave Pharmaceuticals, a pediatric focused specialty pharmaceutical company, which was sold to Pfizer for a total of $700 million in upfront and milestone payments. From 1993 to May 2003 he was the chairman and CEO of First Horizon Pharmaceuticals, a publicly traded specialty pharmaceutical company, where he raised over $200 million and built a highly profitable company before it was sold to Shionogi Pharmaceuticals for $1.4 billion.

Marian Asch, Sales Manager Inhalation Technologies at Harro Hoefliger

Marian Asch has a BSc. degree in business and engineering from University of Stuttgart.
He started his career as Project Manager in Harro Hoefligers Business Unit Inhalation in 2017. In this role he managed DPI projects of multinational pharma clients worldwide. Since summer 2021, Marian Asch works as a Sales Manager for Inhalation Technologies focusing on business development and sales for dry powder inhaler pharma industry.

Mark Parry, Technical Director at Intertek Melbourn

Mark Parry has worked with Intertek Melbourn for 20 years after graduating from Cambridge University and currently works as the Technical Director supporting the wide range of analytical, formulation and product development activities across the company.
Mark has worked in a range of pharmaceutical analysis and formulation development areas with a particular focus on inhaled and nasal drug products. Mostly working in the pre-approval stages, Mark's background includes extensive experience with product and formulation development, as well as method development and validation, stability studies, and pharmaceutical development activities for a wide range of clients across the pharmaceutical industry.

Michael Castagna, Chief Executive Officer at MannKind Corporation

Michael Castagna is Chief Executive Officer and serves on the Board of Directors for MannKind Corporation. Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global Lifecycle Management.

Nitesh Kunda, Assistant Professor at St. John's University

Dr. Nitesh Kunda is an Assistant Professor in Industrial Pharmacy and Pharmaceutics in the Department of Pharmaceutical Sciences within the College of Pharmacy and Health Sciences at St. John's University. Dr. Kunda has numerous high-impact peer-reviewed research publications covering a wide variety of topics including formulation, drug delivery, stabilization and inhaled delivery of vaccines, and health effects due to common environmental toxicants. Dr. Kunda is an active member of the American Association of Pharmaceutical Scientists (AAPS, since 2012) and many other professional organizations.

Philip Wilson, Marketing Director at Celanese

Dr. Philip Wilson is a Marketing Director with the medical polymers business of Celanese Engineered Materials. Philip has a PhD in Physics from the University of Texas at Austin and has worked for 20 years in a wide range of roles in the materials and chemical industry. He enjoys learning about new areas of technology to identify new opportunities for innovation.

Valerie Thomas, Sr. Principal Scientist- Nonclinical Drug Safety at Merck & Co.

Dr. Valerie Thomas is a board-certified veterinary pathologist at Merck, with over 19 years' experience in nonclinical pharmaceutical safety including in the area of medical device combination product safety/biocompatibility. As a Sr. Investigative Scientist in Nonclinical Drug Safety, she works on numerous small molecule and biologic projects across a wide spectrum of therapeutic areas. Certified in biocompatibility of medical devices, she also provides subject matter expertise in preclinical combination product and medical device development at Merck, reviewing and monitoring ISO compliant studies and as author of over 50 worldwide regulatory submissions for a diverse assortment of products, including for respiratory medical device combination products.

Vivek Gupta, Associate Professor, and Scientific Founder at St. John's University; PulmoSIM Therapeutics

Vivek Gupta is an Associate Professor, and Associate Dean of Graduate Education & Research at St. John's University College of Pharmacy. Dr Gupta is an experienced pharmaceutical researcher with interests in developing novel therapies for respiratory disorders. His expertise lies in the fields of novel drug discovery and repurposing, and non-invasive delivery of small and macromolecules via inhalation route. He also has significant research interest in the fields of pharmaceutical scalability, and nano-repurposing. Dr. Gupta's research group has published >75 high-impact studies in peer reviewed journals. Dr. Gupta also serves on editorial boards of many peer-reviewed journals; and is also involved in national pharmaceutical organizations including AAPS and CRS. Multiple technologies and therapies developed by Dr. Gupta's group have been patented and have been licensed to biotech start-ups including PulmoSIM Therapeutics.

Yvonne Limpens, Managing Human Factors Specialist at Emergo by UL

Yvonne Limpens is a Managing Human Factors Specialist with Emergo by UL's Human Factors Research & Design (HFR&D) team based in Utrecht, The Netherlands. She has been with the team since 2013 and has experience delivering HFE services to the medical device, and pharmaceutical industries. Yvonne leads and oversees research activities and helps clients develop key HFE documents for their design history files.


Merrill Lynch

75 Rockefeller Plaza

75 Rockefeller Plaza is a skyscraper on the north side of 51st Street in New York City, originally built as a northern extension to Rockefeller Center. Situated in the heart of Midtown Manhattan, the 75 Rockefeller plaza with a recent $140 million renovation is prepared to offer industry-leading events and personalized service to actualize a modern atmosphere and be the ideal destination for hosting and cultivating your most important relationships.



resconsummit.com